Ameriprise Financial Inc. Sells 3,127,890 Shares of AbbVie Inc. $ABBV

Ameriprise Financial Inc. decreased its stake in AbbVie Inc. (NYSE:ABBV) by 25.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,267,451 shares of the company’s stock after selling 3,127,890 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.52% of AbbVie worth $1,719,101,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Brighton Jones LLC increased its holdings in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Vestmark Advisory Solutions Inc. grew its position in AbbVie by 84.3% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 38,888 shares of the company’s stock worth $8,148,000 after acquiring an additional 17,788 shares during the last quarter. Kovitz Investment Group Partners LLC increased its holdings in AbbVie by 42.7% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 93,218 shares of the company’s stock valued at $19,531,000 after purchasing an additional 27,890 shares in the last quarter. Finally, Azimuth Capital Investment Management LLC raised its position in AbbVie by 0.3% in the 1st quarter. Azimuth Capital Investment Management LLC now owns 108,098 shares of the company’s stock valued at $22,649,000 after purchasing an additional 339 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Down 0.2%

Shares of NYSE ABBV opened at $223.45 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm’s 50-day moving average is $227.25 and its 200-day moving average is $209.59. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $394.92 billion, a PE ratio of 169.28, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the firm posted $3.00 earnings per share. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ABBV. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Bank of America upped their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $244.55.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.